Literature DB >> 19255111

Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus.

Jairo Gooskens1, Marcel Jonges, Eric C J Claas, Adam Meijer, Peterhans J van den Broek, Aloyj M Kroes.   

Abstract

CONTEXT: The sudden emergence and rapid spread of oseltamivir-resistant influenza A(H1N1) viruses with neuraminidase (NA) gene H274Y amino acid substitution is the hallmark of global seasonal influenza since January 2008. Viruses carrying this mutation are widely presumed to exhibit attenuated pathogenicity, compromised transmission, and reduced lethality.
OBJECTIVE: To investigate nosocomial viral transmission in a cluster of patients with influenza A(H1N1) virus infection. DESIGN, SETTING, AND PATIENTS: Descriptive outbreak investigation of 2 hematopoietic stem cell transplant recipients and an elderly patient who developed hospital-acquired influenza A virus infection following exposure to an index patient with community-acquired H274Y-mutated influenza A(H1N1) virus infection in a medical ward at a Dutch university hospital in February 2008. The investigation included a review of the medical records, influenza virus polymerase chain reaction and culture, phenotypic oseltamivir and zanamivir susceptibility determination, and hemagglutinin chain 1 (HA(1)) gene and NA gene sequence analysis. MAIN OUTCOME MEASURE: Phylogenetic relationship of patient cluster influenza A(H1N1) viruses and other 2007-2008 seasonal influenza A(H1N1) viruses.
RESULTS: Viral HA(1) and NA gene sequence analysis from the 4 patients revealed indistinguishable nucleotide sequences and phylogenetic clustering of H274Y-mutated, oseltamivir-resistant influenza A(H1N1) virus, confirming nosocomial transmission. Influenza virus pneumonia (3 patients) and attributable mortality (2 patients) during active infection was observed in patients with lymphocytopenia at onset.
CONCLUSION: Seasonal oseltamivir-resistant influenza A(H1N1) viruses with NA gene H274Y mutation are transmitted and retain significant pathogenicity and lethality in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255111     DOI: 10.1001/jama.2009.297

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  39 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

2.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.

Authors:  Gallen B Triana-Baltzer; Rebecca L Sanders; Maria Hedlund; Kellie A Jensen; Laura M Aschenbrenner; Jeffrey L Larson; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2010-11-21       Impact factor: 5.790

4.  In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

Authors:  Katrina Sleeman; Vasiliy P Mishin; Varough M Deyde; Yousuke Furuta; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

Review 5.  How I treat influenza in patients with hematologic malignancies.

Authors:  Corey Casper; Janet Englund; Michael Boeckh
Journal:  Blood       Date:  2009-12-15       Impact factor: 22.113

6.  Caveolin-1 influences human influenza A virus (H1N1) multiplication in cell culture.

Authors:  Lijing Sun; Gun-Viol Hemgård; Sony A Susanto; Manfred Wirth
Journal:  Virol J       Date:  2010-05-26       Impact factor: 4.099

Review 7.  Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

Authors:  Regina Dutkowski
Journal:  J Antimicrob Chemother       Date:  2010-04       Impact factor: 5.790

8.  Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy.

Authors:  Susanna Esposito; Claudio Giuseppe Molteni; Cristina Daleno; Antonia Valzano; Emilio Fossali; Liviana Da Dalt; Valerio Cecinati; Eugenia Bruzzese; Raffaella Giacchino; Carlo Giaquinto; Carlotta Galeone; Angie Lackenby; Nicola Principi
Journal:  Virol J       Date:  2010-08-26       Impact factor: 4.099

9.  Safety of oseltamivir compared with the adamantanes in children less than 12 months of age.

Authors:  David W Kimberlin; Marwan Shalabi; Mark J Abzug; David Lang; Richard F Jacobs; Gregory Storch; John S Bradley; Kelly C Wade; Octavio Ramilo; José R Romero; Mark Shelton; Charles Leach; Judith Guzman-Cottrill; Joan Robinson; Nazha Abughali; Janet Englund; Jill Griffin; Penny Jester; Gretchen A Cloud; Richard J Whitley
Journal:  Pediatr Infect Dis J       Date:  2010-03       Impact factor: 2.129

10.  Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.

Authors:  Gallen B Triana-Baltzer; Larisa V Gubareva; Alexander I Klimov; David F Wurtman; Ronald B Moss; Maria Hedlund; Jeffrey L Larson; Robert B Belshe; Fang Fang
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.